Chronic Obstructive Pulmonary Disease (COPD) refers to a group of progressive lung conditions that cause long-term obstruction of airflow, making it difficult to breathe. The condition primarily includes emphysema and chronic bronchitis, and many patients exhibit symptoms of both. In emphysema, the alveoli (air sacs) are damaged and enlarged, leading to shortness of breath or dyspnea. Chronic bronchitis involves inflammation and narrowing of the large airways, resulting in excessive mucus production and persistent coughing. The chronic obstructive pulmonary disease (COPD) market is expected to grow from USD 22.15 billion in 2025 to USD 48.78 billion by 2032, registering a compound annual growth rate (CAGR) of 6.8% over the forecast period from 2025 to 2032.
Key facts
· According to the World Health Organization (WHO), COPD was the fourth leading cause of death globally in 2021, responsible for approximately 3.5 million deaths, or 5% of all global deaths.
· Nearly 90% of COPD-related deaths among individuals under 70 years occur in low- and middle-income countries (LMI Cs).
· The disease also ranks as the eighth leading cause of poor health worldwide, measured in disability-adjusted life years (DALYs).
· Tobacco smoking remains the most significant risk factor, accounting for over 70% of COPD cases in high-income countries, while in LMICs, 30–40% of cases are linked to smoking, with household air pollution serving as another major contributor.
Market Drivers: Rising Prevalence and Growing Awareness
The primary driver of the COPD market is the escalating incidence of respiratory diseases globally, fueled by smoking, air pollution, and an ageing population. According to the World Health Organization, COPD accounted for approximately 3.5 million deaths in 2021, representing around 5% of all global deaths. Increasing awareness of disease management, early diagnosis, and preventive measures is propelling the adoption of advanced therapies, inhalers, and combination treatments. Additionally, expanding healthcare infrastructure, particularly in emerging markets, is facilitating better access to diagnosis and treatment, further boosting market demand.
Opportunities: Innovation and Emerging Markets
The COPD market is ripe with opportunities arising from innovative drug formulations, novel inhalation devices, and biologics designed to improve patient outcomes. Growing focus on personalized medicine and the development of digital health solutions, such as connected inhalers and remote monitoring tools, is expected to enhance patient adherence and therapeutic efficacy. Emerging economies, particularly in Asia-Pacific and Latin America, present significant growth potential due to rising disease prevalence, increasing healthcare expenditure, and improving access to modern therapies. Strategic collaborations, product launches, and technology-driven solutions offer manufacturers and healthcare providers the opportunity to capture new market segments.
Challenges: Market Complexity and Accessibility Barriers
Despite growth potential, the COPD market faces several challenges, including the high cost of advanced therapies, limited patient awareness in low- and middle-income countries, and disparities in healthcare access. Complex treatment regimens, patient non-adherence, and regulatory hurdles across different regions can impede market expansion. Additionally, environmental risk factors such as air pollution and occupational exposure continue to exacerbate disease incidence, creating an ongoing need for public health initiatives alongside commercial solutions. Manufacturers must address these barriers through education campaigns, affordable solutions, and localized strategies to ensure sustainable growth.
Global Initiatives and Investment in the COPD Market
Healthcare systems, governments, and private organizations worldwide are increasingly prioritizing initiatives to combat Chronic Obstructive Pulmonary Disease (COPD), reflecting the growing disease burden and the market’s investment potential.
Government and Public Health Initiatives
Several countries have launched nationwide COPD awareness, prevention, and management programs. In Europe, countries such as the UK, Germany, and France have implemented early-diagnosis campaigns, smoking cessation programs, and national COPD registries to improve patient outcomes and monitor disease prevalence. In North America, the U.S. National Heart, Lung, and Blood Institute (NHLBI) supports COPD-focused research, patient education campaigns, and funding for pulmonary rehabilitation programs. Emerging economies like China, India, and Brazil are investing in community-level awareness programs and healthcare infrastructure to address high COPD prevalence caused by tobacco use and air pollution.
Pharmaceutical and Biotech Investments
Global pharmaceutical companies are actively investing in COPD drug development, inhaler device innovation, and combination therapies. Companies such as GlaxoSmithKline, AstraZeneca, Novartis, and Boehringer Ingelheim are funding clinical trials for next-generation inhaled medications, biologics, and dual bronchodilator therapies. Biotech startups are attracting venture capital to develop targeted therapies, including anti-inflammatory biologics and personalized treatment solutions. Private equity and strategic partnerships between large pharma and specialty biotech firms are increasingly common to accelerate pipeline development and global distribution.
Digital Health and Technological Advancements
Investment is also flowing into digital therapeutics and connected devices. Smart inhalers, remote patient monitoring, and AI-powered adherence platforms are being developed to improve patient compliance and provide real-time treatment feedback. Companies in the U.S., Europe, and Asia-Pacific are collaborating with technology firms and digital health startups to integrate data analytics into disease management, providing new revenue streams and enhancing clinical outcomes.
Global Collaborative Efforts
International organizations such as the World Health Organization (WHO) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) are driving worldwide COPD programs, supporting research, guidelines, and advocacy. These initiatives encourage multinational investments in both public and private sectors, fostering global collaboration on COPD management strategies, drug development, and awareness campaigns.
Key Developments:
In July 2025, Merck announced a definitive agreement to acquire Verona Pharma plc, a biopharmaceutical company specializing in respiratory diseases. Under the terms of the deal, Merck will acquire Verona Pharma for $107 per American Depository Share (ADS)—each representing eight ordinary shares—valuing the transaction at approximately $10 billion. With this acquisition, Merck will add Ohtuvayre (ensifentrine) to its expanding cardio-pulmonary pipeline. Ohtuvayre is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), offering a novel approach to treating respiratory conditions.
In September 2024, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. This approval marks a significant milestone, as Dupixent becomes the first biologic medicine approved in the U.S. for this specific patient population.
On May 22, 2025, GSK plc announced that the U.S. Food and Drug Administration (FDA) had approved Nucala® (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. This approval further expands the treatment options for COPD patients with elevated eosinophil levels.
On November 23, 2023, global pharmaceutical company Lupin Limited announced the launch of Vilfuro-G®, the world’s first fixed-dose triple combination drug (FDC) for the treatment of chronic obstructive pulmonary disease (COPD). Approved by the Drug Controller General of India, the product is delivered via a Dry Powder Inhaler (DPI) and marks a significant milestone in COPD management in India.
Future Outlook
The global COPD market is poised for steady growth over the next decade, driven by rising disease prevalence, increasing healthcare access in emerging markets, and continuous innovation in drug formulations and delivery devices. Advanced therapies, including combination inhalers, biologics, and personalized treatment solutions, are expected to gain traction, improving patient outcomes and adherence. Digital health integration, such as connected inhalers and remote monitoring platforms, will further enhance disease management and create new revenue opportunities. Expansion of public health initiatives, coupled with rising awareness and early-diagnosis programs, will support broader adoption of treatment options. Emerging markets in Asia-Pacific and Latin America are projected to be key growth engines due to increasing healthcare expenditure and urbanization. Overall, the market is set to experience robust innovation-led growth while addressing unmet needs, creating attractive prospects for manufacturers, investors, and healthcare stakeholders globally.
About Author:
HTF Market Intelligence Consulting is uniquely positioned to empower and inspire with research and consulting services to empower businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events, and experience that assist in decision-making.